

Amendment Tool

v1.8 30 April 2025

For office use

QC: No

Section 1: Project information

Short project title*:	COLLABORATE			
IRAS project ID* (or REC reference if no IRAS project ID is available):	337660			
Sponsor amendment reference number*:	Non-substantial amendment 1			
Sponsor amendment date* (enter as DD/MM/YY):	13 January 2026			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	1) Addition of participating NHS sites 2) Minor updates to the COLLABORATE PIS Part 1 (new version 2.1 dated 12/12/2025), Verbal Consent Statement (new version 2.1 dated 12/12/2025) and Sub-Study Informed Consent Form (new version 1.1 dated 15/12/2025) 3) Minor updates to the COLLABORATE protocol (new version 3.0 dated 09/01/2026), including further clarification of sections, addition of registry number and statisticians name, grammatical and formatting updates, and update to MRI scan window for mechanistic sub-study			
Project type (select):	Specific study			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	Yes		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	NHS/HSC REC			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a modified amendment (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		No	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	Yes	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	Yes		No	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		No	
Was the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device [^] (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		No	
Does the amendment make the study a performance evaluation study of an In Vitro Diagnostic (IVD) medical device [^] (including as a companion diagnostic in a clinical trial of an investigational medicinal product)?:	Yes		No	
[^] IVD medical devices are tests used on biological samples, such as tissues, blood or urine, to determine the status of a person's health. This may be a reagent, reagent product, calibrator, control material, kit, instrument, apparatus, equipment or system, whether used alone or in combination				
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		No	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		No	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	Yes		No	
Does the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?: (e.g. the study relies upon section 251 support in England and Wales, or equivalent in Scotland to set aside the common law duty of confidentiality)	Yes		No	
Does the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		No	
Does the study involve children OR does the amendment introduce this?:	Yes		No	
Did the study involve NHS/HSC organisations prior to this amendment?:	Yes		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		No	
	England	Wales	Scotland	Northern Ireland

Lead nation for the study:	Yes	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	Yes	No	Yes	Yes
Which nations will have participating NHS/HSC organisations after this amendment?	Yes	Yes	Yes	Yes

Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Participating Organisations			
Specific change (select - only available when area of change is selected first)*:	Addition of sites undertaking the same activities as existing sites			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Addition of the following participating sites: The Royal London Hospital, Whipps Cross Hospital, Newham Hospital (Barts Health NHS Trust) - PI: Lucy Fullerton Ninewells Hospital (NHS Tayside) - PI: Birgit Wefers Borders General Hospital (NHS Borders) - PI: Emma Allan University Hospital of Wales (Cardiff and Vales University Health Board) - PI: Zoe Howard West Middlesex University Hospital (Chelsea and Westminster Hospital NHS Foundation Trust) - PI: Luke Mills Northwick Park Hospital (London North West University Healthcare NHS Trust) - PI: Brindha Soundaram Muthusamy Lister Hospital (East and North Hertfordshire Teaching NHS Trust) - PI: Charu Bhatia Victoria Hospital (NHS Fife) - PI: Masooma Ali St Johns Hospital (NHS Lothian) - PI: David Quine Queen's Hospital Burton (University Hospitals of Derby and Burton NHS Foundation Trust) - PI: Shalini Ojha			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers. In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Minor change to PIS Part 1 (new version 2.1 dated 12/12/2025) - including updating formatting, confirming ePARCA is part of routine care, removing central team contact details, as local team contact is provided. Minor change to Verbal Consent Statement (new version 2.1 dated 12/12/2025) - removing central team contact details, as local team contact is provided. Minor change to Sub-Study ICF (new version 1.1 dated 15/12/2025) - correction of a typo and confirmation that clause 13 is optional.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes

Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All	Some
		Remove all changes below

Change 3				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Non-substantial changes (e.g. not affecting safety or the scientific value of the trial)			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	•Addition of ISRCTN registration number •Minor updates to nutritional supplements and faltering growth section and clarification that further guidance will be provided in the study manual •Addition of study statistician name •Formatting, typographical and grammatical updates •Updated Schedule of Assessments table for further clarity •Minor clarifications to section 5.2.2.2 (For babies participating in the mechanistic sub-study), 5.8 (Lab evaluations), and 6.8 (Adverse reaction reporting) •Update to MRI window for mechanistic sub-study to 37-44 weeks PMA, this will ensure site teams have a longer window to schedule the MRI scan			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
				Remove all changes below

Change 4				
Area of change (select)*:	Researchers			
Specific change (select - only available when area of change is selected first)*:	Changes to the research team (other than CIs or PIs)			
Further information: explain what the change is, why the change is being made and any possible impact on study participants/carers (free text - note that this field will adapt to the amount of text entered):	Study statistician has been appointed and is now in post: Martin Orr			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? (please note that this answer may affect the categorisation for the change):	All		Some	
				Add another change

Section 3: Declaration(s) and lock for submission

Declaration by the Sponsor or authorised delegate	
• I confirm that the Sponsor takes responsibility for the completed amendment tool • I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf	
Name [first name and surname]*:	Eleanor Izzard
Email address*:	e.izzard@imperial.ac.uk

Lock for submission
Please note: This button will only become available when all mandatory (*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, [proceed to submit the amendment online](#). The "Submission Guidance" tab provides further information about the next steps for the amendment.

Section 4: Review bodies for the amendment

Please note: This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies														Category:				
	UK wide:						England and Wales:				Scotland:		Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function		HSC REC	HSC Data Guardians	Prisons	National coordinating function
Change 1:						Y				Y				(Y)				(Y)	New site
Change 2:						(Y)				(Y)				(Y)				(Y)	C
Change 3:						(Y)				(Y)				(Y)				(Y)	A
Change 4:						N				N				N				N	N/A
Overall reviews for the amendment:																			
Full review:						Y				Y				N				N	
Notification only:						N				N				Y				Y	
Overall amendment type:	Non-substantial																		
Overall Category:	A																		
For national coordinating function office use:																			
New nation(s):	This amendment adds new participating nation(s) for the first time: Wales. Ensure that HARP is updated.																		